There are an estimated 40 million women in the United States currently experiencing the transition from peri-menopausal to post-menopausal states. In the next decade an additional 20 million women are expected to reach this life milestone. Unfortunately, this transitional state is associated with a number of troubling signs and symptoms that impact the quality of life, including hot flashes, night sweats, osteoporosis, sleep disorders, and loss of libido. Hypoactive sexual desire disorder (HSDD), commonly classified as a component of female sexual dysfunction (FSD), is characterized as a persistent absence of sexual fantasies or thoughts and/or desire for and receptivity to sexual activity that causes distress.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. (ITI), is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the central nervous system (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS including schizophrenia, sleep disorders, Parkinson's and Alzheimer's disease, cognitive deficits in schizophrenia, depression and female sexual dysfunction and other disorders pertaining to women's health. To aid in the development process, the Company incorporates its CNSProfile(TM), a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases.
Earlier this year, ITI initiated Phase I clinical programs for
schizophrenia and sleep maintenance disorders. ITI-007, the Company's
first-in-class dual 5HT2A receptor antagonist/dopamine receptor
phosphoprotein modulator (DPPM) is being studied for the treatment of
schizophrenia. ITI-722, a low dose formulation of ITI-007 with selective
5HT2A receptor an
|SOURCE Intra-Cellular Therapies|
Copyright©2007 PR Newswire.
All rights reserved